SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 4. P. 71-80

REVIEW

A.A. Danilenko, S.V. Shakhtarina

Radiation Therapy of Hodgkin’s Lymphoma: From “Radical Program” of Treatment to Modern Technologies

A.F. Tsyb Medical Radiological Research Center, Obninsk, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

First significant achievements in treatment of Hodgkin’s lymphoma patients were obtained due to radiation therapy. Compound chemotherapy introduced later also yielded considerable results. Combined modality of these two methods produced the most effective treatment. Radiation therapy gradually underwent changes as a result of technical innovations and improving concept of optimal treatment volumes and doses. The review presents literature data on the history of radiation therapy for Hodgkin’s lymphoma patients used alone, and in combination with chemotherapy.

Key words: Hodgkin’s lymphoma, radiotherapy, chemo-radiotherapy

REFERENCES

  1. Lukes R.J., Butler J.J. The pathology and nomenclature of Hodgkin’s disease. Cancer Res. 1966. Vol. 26. No. 6. P. 1063-1083.
  2. Kaplan H.S., Rosenberg S.A. The management of the Hodgkin’s disease. Cancer, 1975. Vol. 36. No. 2. P. 796-803.
  3. Glatstein E., Guernsey J.M., Rosenberg S A. et al. The value of laparotomy and splenectomy in the staging of Hodgkin’s disease. Cancer, 1969. Vol. 24. No. 4. P. 709-718.
  4. Carbone P.P., Kplan H.S., Musshoff K. et al. Report of the Committee on Hodgkin’s disease staging classification. Cancer Res. 1971. Vol. 31. No. 11. P. 1860-1961.
  5. Lister T.A., Crowther D., Sutcliffe S.B. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswold’s meeting. J. Clin. Oncol. 1989. Vol. 7. No. 11. P. 1630-1636.
  6. Meignan M., Gallarnini A., Itti E. et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk. Lymphoma, 2012. Vol. 53. No. 10. P. 1876-1881.
  7. Kaplan H.S. Long-term results of palliative and radical radiotherapy of Hodgkin’s disease. Cancer Res. 1966. Vol. 26. No. 1. P. 1250-1252.
  8. Baisogolov G.D., Khmelevskaya Z.I. Luchevaya terapiya limfogranulematoza po radikal'noi programme (metodicheskie rekomendatsii). Minzdrav SSSR, Akademiya med. nauk SSSR. 1972. 45 p. (In Russ.).
  9. Shakhtarina S.V., Pavlov V.V., Danilenko A.A., Afanasova N.V. Lechenie bol'nykh limfomoi Khodzhkina s lokal'nymi stadiyami I, II, IE, IIE: opyt Meditsinskogo radiologicheskogo nauchnogo tsentra. Klinicheskaya onkogematologiya, 2007. No. 4. P. 36-46. (In Russ.).
  10. Duhmke E., Franklin J., Pfreundschuh M. et al. Lowdose radiation is sufficient for the non involved extended field treatment in vavorable early stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J. Clin. Oncol. 2001. Vol. 19. No. 11. P. 2905-2914.
  11. Huguley C.M., Durant J.R., Moores R.R., at al. A comparison of nitrogen mustard, vincristine, procarbasine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin’s disease. Cancer. 1975. Vol. 36. No. 4. P. 1227-1240.
  12. Canellos G.P., Rosenberg S.A., Friedberg J.W. et al. Treatment of Hodgkin’s lymphoma: A 50-year perspective. J. Clin. Oncol. 2014. Vol. 32. No. 3. P. 163-168.
  13. Bonadonna G., Zucali R., Monfardini S. et al. Combunation chemotherapy of Hodgkin’s diseasewith adriamycin, vinblastine, and imidazole carboxiamide versus MOPP. Cancer. 1975. Vol. 36. No. 1. P. 252-259.
  14. Canellos G.P., Niedzwiecki D., Johnston J.L. Longterm follow up of survival in Hodgkin’s lymphoma. N. Engl. J. Med. 2009. Vol. 361. No. 24. P. 2390-2391.
  15. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N. Engl. J. Med. 1998. Vol. 339. No. 21. P. 1506-1514.
  16. Diehl V., Franklin J., Hasenclever D. et al. BEACOPP: a new regimen for advanced Hodgkin’s disease - German Hodgkin’s Lymphoma Study Group. Ann. Oncol. 1998. Vol. 9. Suppl. 5. P. 67-71.
  17. Horning S.G., Hoppe R.T., Breslin S. et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J. Clin. Oncol. 2002. Vol. 20. No. 3. P. 630-637.
  18. Kelly K.M., Sposto R., Hutchinson R. et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood. 2011. Vol. 117. No. 9. P. 2596-2603.
  19. Fuller L.M., Hagemeister F.B., North L.B. et al. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage I through IIB Hodgkin’s disease: preliminary results. Int. J. Radiat. Biol. Phys. 1988. Vol. 14. No. 4. P. 683-692.
  20. Longo D.L., Glatstein E., Duffey P.L. et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J. Clin. Oncol. 1991. Vol. 9. No. 6. P. 906-917.
  21. Shakhtarina S.V. Luchevoe, polikhimio-luchevoe, lekarstvennoe lechenie pervichnykh form limfogranulematoza I-IV stadii. Obninsk. Diss. dokt. med. nauk. 1995. 413 p. (In Russ.).
  22. Lister T.A. Treatment of stage IIIa Hodgkin’s disease: Long follow-up perspective. J. Clin. Oncol. 2008. Vol. 26. No. 2. P. 5144-5146.
  23. Shakhtarina S.V. Kombinirovannoe (luchevoe i lekarstvennoe) lechenie bol'nykh limfogranulematozom I-II stadii. Obninsk, diss. kand. med. nauk. 1985. 175 p. (In Russ.).
  24. Straus D.J., Portlock C.S., Qin G. et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by r5adiation therapy (RT) versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin’s disease. Blood. 2004. Vol. 104. No. 12. P. 3483-3489.
  25. Campbell B.A., Hornby C., Cunninghame J. et al. Minimising critical organ irradiation in limited stage Hodgkin’s lymphoma: A dosimetric study of the benefit of involved node radiotherapy. Ann. Oncol. 2012. Vol. 23. No. 5. P. 1259-1266.
  26. Isaev I.G. Luchevaya terapiya v kombinirovannom lechenii bol'nykh limfogranulematozom IIIB-IV stadii. Obninsk. Diss. kand. med. nauk. 1981. 182 p. (In Russ.).
  27. Zittoun R., Audebert A., Hoerni B. et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J. Clin. Oncol. 1985. Vol. 3. No. 2. P. 207-214.
  28. Datsenko P.V. Metodika luchevoi terapii s poetapnym zonal'nym sokrashcheniem polei. V kn.: «Limfoma Khodzhkina». OOO «TID «Russkoe slovo-RS». 2009. P. 145-148. (In Russ.).
  29. Shakhtarina S.V., Pavlov V.V., Danilenko A.A., Lashkova O.E. Treatment of Hodgkin’s disease patients with radio-chemotherapy using reduced (20-30 Gy) total tumor doses. Abstracts for the 6th Symp. On Hodgkin’s lymphoma. Cologne, Germany. 18-21 Sept. 2004. Haematol. 2004. Vol. 73. Suppl. 65. P. 39-40.
  30. Shakhtarina S.V., Danilenko A.A., Pavlov V.V., Dvinskikh N.Yu. Kombinirovannoe lechenie pervichnykh bol'nykh limfomoi Khodzhkina I-II stadii s primeneniem luchevoi terapii v umen'shennykh summarnykh ochagovykh dozakh (20-30 Gr) i khimioterapii po skhemam SORR, ABVD, BEACOPP-21. Mat-ly nauchno-prakt. konf. «Aktual'nye voprosy diagnostiki i lecheniya limfomy Khodzhkina (po rezul'tatam lechebnykh programm 1998-2008 g.)». 15-17 Apr. 2010. Obninsk. 64 p. (In Russ.).
  31. Minimal'nye klinicheskie rekomendatsii Evropeiskogo obshchestva meditsinskoi onkologii (ESMO). Moscow, publ. gruppa RONTs im. N.N. Blokhina RAMN. 2010. 433 p. (In Russ.).
  32. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. Under the guidance of I.V. Poddubnoi, V.G. Savchenko. Moscow: Media Medika, 2013. 102 p. (In Russ.).
  33. Meyer R.M., Gospodarovicz M.K., Connors J.M. et al. ABVD alone versus radiation-based therapy in limitedstage Hodgkin’s lymphoma. N. Engl. J. Med. 2012. Vol. 366. No. 5. P. 399-408.
  34. Bonadonna G., Bonfante V., Viviani S. et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J. Clin. Oncol. 2004. Vol. 22. No. 14. P. 2835-2841.
  35. Ferme C., Eghbali H., Meerw3aldt J.H. et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N. Engl. J. Med. 2007. Vol. 357. No. 19. P. 1916-1927.
  36. Franklin J., Pluetshow A., Paus M.D. et al. Second malignancy risk associated with treatment for Hodgkin’s lymphoma: meta-analysis of the randomized trials. Ann. Oncol. 2006. Vol. 17. No. 12. P. 1749-1760.
  37. Engert A., Plutschow A., Eich H.T. et al. Reduced treatment intensity in patients with early stage Hodgkin’s lymphoma. N. Engl. J. Med. 2010. Vol. 363. No. 7. P. 640-652.
  38. Eich H.T., Diehl V., Gorgen H. et al. Intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J. Clin. Oncol. 2010. Vol. 28. No. 27. P. 4199-4206.
  39. Gallamini A., Hutchings M., Rigacci L. et al. Early interim 2- [18F] fluoro-2-depxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish study. J. Clin. Oncol. 2007. Vol. 25. No. 24. P. 3746-3752.
  40. Press O.W., LeBlanc M., Rimsza H. et al. Front-line treatment of Hodgkin’s lymphoma - A phase II trial of responce-adapted therapy of Stage III-IV Hodgkin’s lymphoma using early interim FDG-PET imaging: US Intergroup S0816. Hematol. Oncol. 2013. Suppl. 1. Abstr. 124.
  41. Girinsky T., van der Maazen R., Specht L. et al. Involve-node radiotherapy (INRT) in patients with early Hodgkin’s lymphoma: concepts and guidelines. Radiother. Oncol. 2006. Vol. 79. No. 3. P. 270-277.
  42. Raemaekers J.M., Andre M.P., Federico M. et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin’s lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J. Clin. Oncol. 2014. Vol. 32. No. 12. P. 1188-1194.
  43. Available from: http://en.ghsg.org/active-trials/articles/hd16-study.
  44. Radford J., Barrington S., Counsell N. et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin’s lymphoma and a “negative” PET scan after 3 cycles ABVD: Results of the UK NCRI RAPID Trial. Blood. 2012. Vol. 120. Abstr. 547.
  45. Filippi A.R., Boticella A., Bello M. et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin’s lymphoma treated with combined modality therapy. Leuk. Lymph. 2013. Vol. 54. No. 6. P. 1183-1187.
  46. Gallamini A., Barrington S.F., Biggi A. et al. The predictive role of interim positron emission tomography for Hodgkin’s lymphoma treatment outcome in confirmed using the interpretation criteria of the Deauville fivepoint scale. Haematol. 2014. Vol. 99. No. 6. P. 1107-1113.
  47. Jahalom J., Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann. Oncol. 2002. Vol. 13. Suppl. 1. P. 79-83.
  48. Maraldo M.V., Brodin P., Aznar M.C. et al. Estimated risc of cardiovascular disease and secondari cancers with modern highly conformal radiotherapy for early stage mediastinal Hodgkin’s lymphoma. Ann. Oncol. 2013. Vol. 24. No. 8. P. 2113-2118.
  49. Ricardi U., Filippi A.R., Piva C., Franco P. The evolving role of radiotherapy in early stage Hodgkin’s lymphoma. Mediter. Hematol. Infect. 2014. Vol. 6. No. 1. DOI: 10.4084/MJHID.2014.035.
  50. Campbell B.A., Hornby C., Cunninghame J. Minimising critical organ irradiation in limited stage Hodgkin’s lymphoma: A dosimetric study of the benefit of involved node radiotherapy. Ann. Oncol. 2012. Vol. 23. No. 50. P. 1259-1266.
  51. De Bruin M.L., Sparidans J., van’t Veer M.B. et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J. Clin. Oncol. 2009. Vol. 27. No. 26. P. 4239-4246.
  52. Maraldo M.V., Aznar M.C., Vogelius I.R. et al. Involved node radiation therapy: an effective alternative in earlystage Hodgkin’s lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 2013. Vol. 85. No. 4. P. 1057-1065.
  53. Engert A., Horning S.J. Hodgkin Lymphoma: a Comprehensive Update on Diagnostics and Clinics. Berlin - Heidelberg. 2011. 381 p.
  54. Younes A., Gopal A.K., Smith S.E. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 2012. Vol. 30. No. 18. P. 2183-2189.
  55. Deluca P., Jones D., Gahbauer R. et al. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT [report 83]. JICRU. 2010. Vol. 10. No. 1. P. 1-106.
  56. Specht L., Yahalom J., Illidge T. et al. ILROG. Modern radiation therapy for Hodgkin’s lymphoma: Field and dose guidelines from the International lymphoma radiation oncology group (ILROG). Int. J. Radiat. Biol. Phys. 2014. Vol. 89. No. 4. P. 854-862.
  57. Goda J.S., Massey C., Kuruvilla J. et al. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant. Int. J. Radiat. Biol. Phys. 2012. Vol. 84. No. 3. P. 329-335.

For citation: Osovets S.V. Revisiting the Theory of Radiation Injury and Recovery. Medical Radiology and Radiation Safety. 2015;60(4):71-80. Russian.

PDF (RUS) Full-text article (in Russian)

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх